ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years
Zhengtao Hong
Matched on OpenAlex author ID A5071694248. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 4
- Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. Co-author DOI 10.1186/s13046-025-03323-9↗
- Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021↗
- Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. Co-author DOI 10.1016/j.ebiom.2022.103958↗
- Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. Co-author DOI 10.1136/jitc-2021-004129↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tingbo Liang · 4 shared papers, 2022–2025 · strength 0.76
- Paper Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. DOI 10.1186/s13046-025-03323-9↗
- Paper Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. DOI 10.1136/jitc-2021-004129↗
- Paper Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combi… DOI 10.1016/j.ebiom.2022.103958↗
- Xueli Bai · 3 shared papers, 2022–2025 · strength 0.60
- Paper Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. DOI 10.1186/s13046-025-03323-9↗
- Paper Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combi… DOI 10.1016/j.ebiom.2022.103958↗
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021↗
- Xing Huang · 2 shared papers, 2022–2025 · strength 0.49
- Xiao Zhi · 1 shared paper, 2022 · strength 0.16
- Gang Zhang · 1 shared paper, 2022 · strength 0.16
- Junming Huang · 1 shared paper, 2022 · strength 0.16
- Tianyu Tang · 1 shared paper, 2022 · strength 0.16
- Qi Zhang · 1 shared paper, 2022 · strength 0.14
- Jiaqi Yang · 1 shared paper, 2022 · strength 0.14
- Hanshen Yang · 1 shared paper, 2023 · strength 0.14
- Lihong He · 1 shared paper, 2023 · strength 0.14
- Kang Sun · 1 shared paper, 2023 · strength 0.14
- Xiaozhen Zhang · 1 shared paper, 2023 · strength 0.14
- Mengyi Lao · 1 shared paper, 2023 · strength 0.14
- Yifan Hong · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.